22 research outputs found
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors. First published in 2004 and updated in 2010, the GC edition 2016 answers to the need for updated recommendations for the training of physicians in medical oncology by defining the standard to be fulfilled to qualify as medical oncologists. At times of internationalisation of healthcare and increased mobility of patients and physicians, the GC aims to provide state-of-the-art cancer care to all patients wherever they live. Recent progress in the field of cancer research has indeed resulted in diagnostic and therapeutic innovations such as targeted therapies as a standard therapeutic approach or personalised cancer medicine apart from the revival of immunotherapy, requiring specialised training for medical oncology trainees. Thus, several new chapters on technical contents such as molecular pathology, translational research or molecular imaging and on conceptual attitudes towards human principles like genetic counselling or survivorship have been integrated in the GC. The GC edition 2016 consists of 12 sections with 17 subsections, 44 chapters and 35 subchapters, respectively. Besides renewal in its contents, the GC underwent a principal formal change taking into consideration modern didactic principles. It is presented in a template-based format that subcategorises the detailed outcome requirements into learning objectives, awareness, knowledge and skills. Consecutive steps will be those of harmonising and implementing teaching and assessment strategies
Evaluation of a commercial Dengue NS1 enzyme-linked immunosorbent assay for early diagnosis of dengue infection
Purpose: Dengue is one of the most serious mosquito-borne viral
infections affecting tropical and subtropical countries in the world.
Since there is no immunoprophylactic or specific antiviral therapy
available, timely and rapid diagnosis plays a vital role in patient
management and implementation of control measures. This paper evaluates
a commercially available NS1 antigen capture ELISA vis-a-vis SD bioline
Dengue NS1 antigen test for early detection of dengue virus. Materials
and Methods: To evaluate a commercial NS1 antigen detection kit
vis-a-vis SD bioline Dengue NS1 antigen test, a total of 91 clinical
samples were tested. Virological investigations with regard to dengue
virus, viz. NS1 antigen capture ELISA (Panbio, Australia), SD bioline
Dengue NS1 antigen test, RT-PCR and virus isolation were performed.
Results: Out of 91 samples, 24 (26%) were positive by NS1 antigen
capture ELISA, 15 (16%) by SD bioline Dengue NS1 antigen test and
11(12%) positive by RT-PCR analysis. The RT-PCR-positive samples were
further subjected to virus isolation and resulted in three isolates.
The results of the Panbio NS1 antigen capture ELISA, SD bioline Dengue
NS1 antigen test, RT-PCR and virus isolation were correlated among
themselves. Conclusions: The present study comprehensively established
the utility of NS1 antigen ELISA in early diagnosis of dengue
infection